Electrical Stimulation System

Abstract

To provide an electric stimulation system capable of achieving stabilization of blood sugar fluctuation of a diabetic by generating a combination of electric stimulation pulses and delivering the combination of the electric stimulation pulses to a target skin through an electrode structure, and reducing an inflammatory factor in the body.SOLUTION: An electric stimulation system 1000 includes an electric stimulation generator 1 and at least one electrode structure 2. The electric stimulation generator generates a combination of electric stimulation pulses, and the combination of the electric stimulation pulses is delivered to a target skin through the electrode structure, thereby achieving stabilization of a blood sugar fluctuation and reducing an inflammatory reaction.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an electrical stimulation system and method, and in particular to an electrical stimulation system and method that can achieve stabilization of glycemic excursions and reduce inflammatory responses by generating and delivering a combination of electrical stimulation pulses to a patient. [Background technology]

[0002] Type 2 diabetes is a chronic metabolic disease characterized by hyperglycemia, relative insulin deficiency, and insulin resistance. A complete cure for type 2 diabetes has not yet been developed, and drug therapy remains the most common method to suppress hyperglycemia and diabetic complications. However, taking oral hypoglycemic drugs such as biguanides, sulfonylureas, meglitinides, inhibitors, and GLP-1 analogues can cause discomfort due to side effects (e.g., hypoglycemia), which can lead to a decrease in quality of life, and may cause patients to stop taking the drugs on time. Therefore, there is an urgent need to develop technologies that can supplement or replace current treatment methods with non-pharmacological methods.

[0003] In addition, there is little relevant data on the use of transcutaneous electrical nerve stimulators (TENS) in humans for the treatment or improvement of diabetes. Only a few prior art documents disclosed the use of electrical stimulators to lower glycated hemoglobin (HbA1c) and fasting blood glucose levels in diabetes-induced model mice. There is no description of effectively achieving stabilization of blood glucose fluctuations in humans and suppressing the associated inflammatory state. Summary of the Invention [Problem to be solved by the invention]

[0004] In view of the above circumstances, in order to remedy the problem that the prior art and known electrical stimulation devices cannot be effectively applied to humans to treat type 2 diabetes, the present invention provides an electrical stimulation system that achieves stabilization of blood glucose fluctuations in diabetic patients and reduces inflammatory factors in the body by generating a combination of electrical stimulation pulses and delivering the combination of electrical stimulation pulses to the skin of a subject via an electrode structure. [Means for solving the problem]

[0005] The present invention provides an electrical stimulation system and a method for generating a combination of electrical stimulation pulses, which can improve diabetes-related symptoms. In the electrical stimulation system of the present invention, the generated combination of electrical stimulation pulses is delivered to the body through the human skin via an electrode structure. The electrical stimulation system of the present invention is a non-invasive and portable electrical stimulation system that is more adaptable to humans than current diabetes treatments, without the risk of side effects to humans. In this way, the combination of electrical stimulation pulses generated by the electrical stimulation system can achieve stabilization of blood glucose fluctuations and reduce inflammatory responses.

[0006] In order to achieve the above object, the present invention provides an electrical stimulation system including an electrical stimulation generator and at least one electrode structure. The electrical stimulation generator generates a combination of electrical stimulation pulses. The combination of electrical stimulation pulses has a frequency of 1 to 20,000 Hz. The combination of electrical stimulation pulses is composed of a first frequency group, a second frequency group, and a third frequency group. The first frequency group, the second frequency group, and the third frequency group each are composed of a plurality of monophasic pulse groups. The monophasic pulse groups include: Duty Cycleis 50% or more. The waveform of the monophasic pulse group is a square wave. The electrode structure is electrically connected to the electrical stimulation generator, has a contact surface, and contacts the skin of a subject at the contact surface to deliver the combination of electrical stimulation pulses. The combination of electrical stimulation pulses is output in sequence from the first frequency group to the third frequency group. The frequency range of the first frequency group is 10 to 20,000 Hz. The frequency range of the second frequency group is 1 to 30 Hz. The frequency range of the third frequency group is 5 to 30 Hz.

[0007] In an embodiment of the present invention, the output time of the first frequency group of the combination of electrical stimulation pulses is 2300 to 2350 seconds, the output time of the second frequency group is 900 to 1000 seconds, and the output time of the third frequency group is 320 to 400 seconds.

[0008] In an embodiment of the present invention, the output time of the combination of electrical stimulation pulses is 3520 to 3750 seconds.

[0009] In an embodiment of the invention, said electrical stimulation pulse combination further comprises a potential difference of less than 10 Vpp.

[0010] In an embodiment of the invention, the electrode structure contacts the abdominal skin of the subject.

[0011] In an embodiment of the present invention, the electrical stimulation system improves a diabetic condition by achieving stabilization of blood sugar fluctuations or reducing inflammatory responses.

[0012] In an embodiment of the present invention, the electrical stimulation system achieving stabilization of blood glucose fluctuations is to suppress glycemic variability (GV).

[0013] In an embodiment of the present invention, the electrical stimulation system reduces the inflammatory response by reducing the levels of C-reactive protein (CRP) and fibroblast growth factor 21 (FGF-21) proteins. The reduction of these two proteins also improves organ fibrosis.

[0014] The present invention provides a method for generating a combination of electrical stimulation pulses in the electrical stimulation system. The combination of electrical stimulation pulses generated by the method is delivered to a subject suffering from diabetes via an electrode structure. The monophasic pulse group generated by the method is delivered to the subject transdermally. After acting, it can achieve an effect that could not be achieved by conventional technology, and can reduce inflammatory factors in the body of a diabetic patient and achieve stabilization of blood sugar fluctuations.

[0015] To achieve the above objectives, the present invention provides an electrical stimulation system and method for generating a combination of electrical stimulation pulses.

[0016] Those skilled in the art can understand other objects of the present invention, as well as the technical means and embodiments of the present invention, by referring to the drawings and the embodiments described below. [Brief description of the drawings]

[0017] [Figure 1] 1 is a schematic diagram showing an electrical stimulation system according to the present invention. [Diagram 2] FIG. 1 is a schematic diagram showing the mean amplitude of glycemic excursion (MAGE) of a subject using an electrical stimulation system in an embodiment of the present invention. [Diagram 3] FIG. 2 is a schematic diagram showing the mean amplitude of glycemic excursion (MAGE) of individual groups using an electrical stimulation system in an embodiment of the present invention. [Figure 4]FIG. 2 is a schematic diagram showing the amount of C-reactive protein (CRP), an inflammatory factor, in a subject using an electrical stimulation system according to an embodiment of the present invention. [Diagram 5] FIG. 2 is a schematic diagram showing the amount of fibroblast growth factor 21 (FGF-21), an inflammatory factor, in a subject using an electrical stimulation system in an embodiment of the present invention. [Figure 6] FIG. 2 is a schematic diagram showing a pattern of an electrical stimulation pulse according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present invention will be described below with reference to the embodiments. The embodiments of the present invention are not intended to limit the present invention to a specific environment, application, or special method. Therefore, the description of the embodiments is intended to explain the present invention, and is not intended to limit the present invention. In the embodiments and drawings, components that are not directly related to the present invention are omitted and not shown. In the drawings, the dimensional relationship between the elements is intended to facilitate understanding, and is not intended to limit the actual dimensional ratio.

[0019] FIG. 1 is a schematic diagram showing an electrical stimulation system 1000 according to an embodiment of the present invention. The electrical stimulation system 1000 includes an electrical stimulation generator 1 and two electrode structures 2. The electrical stimulation generator 1 is connected to the two electrode structures 2 via a signal transmission line. The two electrode structures 2 are attached to the abdomen of a subject and deliver a combination of electrical stimulation pulses generated by the electrical stimulation generator 1 to the subject. In this embodiment, the electrical stimulation system 1000 is described as including a signal transmission line and two corresponding electrode structures 2, but this can be adjusted according to the usage situation and demand, and is not limited to this embodiment.

[0020] In this embodiment, the electrical stimulation system 1000 includes an interface module 3 installed in the electrical stimulation system 1000. The interface module 3 is mainly for a user to operate and adjust the electrical stimulation system 1000. The operation and adjustment include a switch for system operation and a command signal for executing default programming. The interface module 3 provides a display screen to the user when a function is being executed, and is not particularly limited in the present invention.

[0021] The electrical stimulation generator 1 generates a combination of electrical stimulation pulses. The combination of electrical stimulation pulses includes a first frequency group, a second frequency group, and a third frequency group. The first frequency group, the second frequency group, and the third frequency group each include a plurality of monophasic pulse groups. The monophasic pulse groups include Duty Cycle is 50% or more. The waveform of the monophasic pulse group is a square wave. The electrical stimulation generator 1 may include a control module, a driving module, and an output module (not shown). The combination of the modules triggers and receives the command signal generated from the interface module 3, outputs the corresponding driving signal, and outputs the electrical stimulation pulses preset in the output program. Duty Cycle , frequency and potential difference. Note that the combination of the control module, the driving module and the output module can be adjusted according to actual needs, and there is no particular limitation in the present invention.

[0022] In this embodiment, the electrode structure 2 is a sheet-like structure, a cloth-like structure, or a wearable device that can be attached to a subject. The electrode structure 2 is electrically connected to an electrical stimulation generator 1 and delivers a combination of electrical stimulation pulses generated from the electrical stimulation generator 1 into the subject's body. The structure of the electrode structure 2 is not limited in the present invention. In detail, the electrode structure 2 has a contact surface that contacts the skin of the subject. In the embodiment of the present invention, the position where the electrode structure contacts is preferably the skin of the abdomen.

[0023] Next, the action frequency of the combination of electrical stimulation pulses will be described. With reference to FIG. 6 as well, the combination of electrical stimulation pulses is output in order from the first frequency group to the third frequency group. The frequency range of the first frequency group is preferably 10 to 20000 Hz, more preferably 13 to 18122 Hz. The frequency range of the second frequency group is preferably 1 to 30 Hz, more preferably 1 to 28 Hz. The frequency range of the third frequency group is preferably 5 to 30 Hz, more preferably 6 to 26 Hz. The output time of the combination of electrical stimulation pulses is preferably 3520 to 3750 seconds, more preferably 3633 seconds. The output time of the first frequency group is preferably 2300 to 2350 seconds, more preferably 2312 seconds. The output time of the second frequency group is preferably 900 to 1000 seconds, more preferably 949 seconds. The output time of the third frequency group is preferably 320 to 400 seconds, more preferably 372 seconds. The output frequency and output time within the frequency ranges of the first frequency group, the second frequency group, and the third frequency group can be adjusted according to actual needs, and are not particularly limited.

[0024] Specifically, in this embodiment, the first frequency group is composed of 47 monophase pulse groups. The monophase pulse groups of the first frequency group include, in order, the following: a first monophase pulse group at 18122 Hz with an output time of 7 seconds, a second monophase pulse group at 10000 Hz with an output time of 15 seconds, a third monophase pulse group at 7344 Hz with an output time of 19 seconds, a fourth monophase pulse group at 5000 Hz with an output time of 24 seconds, a fifth monophase pulse group at 4200 Hz with an output time of 26 seconds, a sixth monophase pulse group at 3672 Hz with an output time of 28 seconds, a seventh monophase pulse group at 3175 Hz with an output time of 30 seconds, and a fifth monophase pulse group at 3200 Hz with an output time of 31 seconds. The eighth single-phase pulse group with an output time of 31 seconds at 000Hz, the ninth single-phase pulse group with an output time of 36 seconds at 2127Hz, the tenth single-phase pulse group with an output time of 35 seconds at 2112Hz, the eleventh single-phase pulse group with an output time of 30 seconds at 2007Hz, the twelfth single-phase pulse group with an output time of 37 seconds at 1865Hz, the thirteenth single-phase pulse group with an output time of 37 seconds at 1850Hz, the fourteenth single-phase pulse group with an output time of 39 seconds at 1550Hz, the fifteenth single-phase pulse group with an output time of 42 seconds at 1234Hz, the fifteenth single-phase pulse group with an output time of 42 seconds at 1043Hz, The 16th monophase pulse group with an output time of 44 seconds, the 17th monophase pulse group with an output time of 45 seconds at 1000Hz, the 18th monophase pulse group with an output time of 45 seconds at 921Hz, the 19th monophase pulse group with an output time of 47 seconds at 880Hz, the 20th monophase pulse group with an output time of 46 seconds at 867Hz, the 21st monophase pulse group with an output time of 45 seconds at 807Hz, the 22nd monophase pulse group with an output time of 57 seconds at 778Hz, the 23rd monophase pulse group with an output time of 49 seconds at 751Hz, the 24th monophase pulse group with an output time of 45 seconds at 730Hz, the 25th monophase pulse group with an output time of 45 seconds at 740Hz, the 26th monophase pulse group with an output time of 45 seconds at 751Hz, the 27th monophase pulse group with an output time of 45 seconds at 760Hz, the 28th monophase pulse group with an output time of 45 seconds at 778Hz, the 29th monophase pulse group with an output time of 45 seconds at 780Hz, the 30th monophase pulse group with an output time of 45 seconds at 780Hz, the 31st monophase pulse group with an output time of 45 seconds at 780Hz, the 32nd monophase pulse group with an output time of 45 seconds at 780Hz, the 33rd monophase pulse group with an output time of 45 seconds at 780Hz, the 34th monophase pulse group with an output time of 45 seconds at 780Hz, the 35th monophase pulse group with an output time of 45 seconds at 780Hz, the 36th monophase pulse group with an output time of 4 4 monophase pulse groups, the 25th monophase pulse group with an output time of 48 seconds at 705Hz, the 26th monophase pulse group with an output time of 54 seconds at 668Hz, the 27th monophase pulse group with an output time of 55 seconds at 652Hz, the 28th monophase pulse group with an output time of 54 seconds at 625Hz, the 29th monophase pulse group with an output time of 51 seconds at 612Hz, the 30th monophase pulse group with an output time of 54 seconds at 595Hz, the 31st monophase pulse group with an output time of 57 seconds at 542Hz, the 32nd monophase pulse group with an output time of 53 seconds at 522Hz,The 33rd monophase pulse group with an output time of 55 seconds at 484Hz, the 34th monophase pulse group with an output time of 56 seconds at 462Hz, the 35th monophase pulse group with an output time of 60 seconds at 435Hz, the 36th monophase pulse group with an output time of 56 seconds at 421Hz, the 37th monophase pulse group with an output time of 60 seconds at 380Hz, the 38th monophase pulse group with an output time of 55 seconds at 348Hz, the 39th monophase pulse group with an output time of 60 seconds at 302Hz, and the 160Hz output time of 69 seconds. The 40th monophase pulse group has an output time of 65 seconds at 141 Hz, the 41st monophase pulse group has an output time of 65 seconds at 125 Hz, the 42nd monophase pulse group has an output time of 72 seconds at 125 Hz, the 43rd monophase pulse group has an output time of 76 seconds at 95 Hz, the 44th monophase pulse group has an output time of 78 seconds at 80 Hz, the 45th monophase pulse group has an output time of 75 seconds at 66 Hz, the 46th monophase pulse group has an output time of 85 seconds at 40 Hz, and the 47th monophase pulse group has an output time of 105 seconds at 13 Hz. The second frequency group is composed of 9 monophase pulse groups. The monophase pulse groups of the second frequency group include, in order: a 48th monophase pulse group at 9 Hz with an output time of 106 seconds, a 49th monophase pulse group at 6 Hz with an output time of 110 seconds, a 50th monophase pulse group at 1 Hz with an output time of 133 seconds, a 51st monophase pulse group at 28 Hz with an output time of 72 seconds, a 52nd monophase pulse group at 19 Hz with an output time of 72 seconds, a 53rd monophase pulse group at 10 Hz with an output time of 24 seconds, a 54th monophase pulse group at 8 Hz with an output time of 144 seconds, a 55th monophase pulse group at 6 Hz with an output time of 144 seconds, and a 56th monophase pulse group at 5 Hz with an output time of 144 seconds. The third frequency group is composed of five monophase pulse groups. The monophasic pulse groups of the third frequency group include, in order: a 57th monophasic pulse group at 6 Hz with an output time of 144 seconds, a 58th monophasic pulse group at 7 Hz with an output time of 144 seconds, a 59th monophasic pulse group at 8 Hz with an output time of 36 seconds, a 60th monophasic pulse group at 17 Hz with an output time of 36 seconds, and a 61st monophasic pulse group at 26 Hz with an output time of 12 seconds.

[0025] In this embodiment, the single-phase pulse groups of the first frequency group are output sequentially. When the previous group is finished, the output frequency of the next group is lower than the previous output frequency. The second frequency group may include a first frequency fluctuation group and a second frequency fluctuation group. The number of single-phase pulse groups in the first frequency fluctuation group is less than the number of single-phase pulse groups in the second frequency fluctuation group. Specifically, the frequency range of the first frequency fluctuation group is preferably 10 to 1 Hz, more preferably 9 to 1 Hz. The output time is preferably 300 to 360 seconds, more preferably 349 seconds. Specifically, the frequency range of the second frequency fluctuation group is preferably 30 to 4 Hz, more preferably 28 to 5 Hz. The output time is preferably 550 to 650 seconds, more preferably 600 seconds.

[0026] As described above, in the first frequency fluctuation group, the 48th single-phase pulse group of 9 Hz, the 49th single-phase pulse group of 6 Hz, and the 50th single-phase pulse group of 1 Hz are output in sequence. When the previous group is finished, the output frequency of the next group is lower than the previous output frequency. In the second frequency fluctuation group, the 51st single-phase pulse group of 28 Hz, the 52nd single-phase pulse group of 19 Hz, the 53rd single-phase pulse group of 10 Hz, the 54th single-phase pulse group of 8 Hz, the 55th single-phase pulse group of 6 Hz, and the 56th single-phase pulse group of 5 Hz are output in sequence. When the previous group is finished, the output frequency of the next group is lower than the previous output frequency. Next, in this embodiment, the single-phase pulse groups of the third frequency group are output in sequence. When the previous group is finished, the output frequency of the next group is higher than the previous output frequency.

[0027] Specifically, the range of the potential difference generated by the electrical stimulation pulse is less than 10 Vpp. The potential difference used in the present invention is a voltage potential difference. Similarly, the potential difference used in the present invention may be a peak-to-peak voltage (Vpp), a maximum voltage (Vmax), or a root-mean-square voltage (Vrms) commonly found in the technical field. The range of the potential difference is preferably 7.2 Vpp or less. The electrical stimulation system 1000 according to the present invention can stably output a voltage potential difference within the above range and provide a voltage potential difference suitable for application to humans.

[0028] In this embodiment, the electrical stimulation system 1000 can improve diabetic symptoms by achieving stabilization of glycemic excursions or reducing inflammatory responses.

[0029] In this embodiment, the electrical stimulation system 1000 can achieve stabilization of glycemic variability (GV) in a diabetic patient by suppressing glycemic variability (GV).

[0030] In this embodiment, the electrical stimulation system 1000 can reduce the inflammatory response in diabetic patients by reducing the amount of C-reactive protein (CRP) and fibroblast growth factor 21 (FGF-21) proteins found in the blood. The reduction of these two proteins also improves organ fibrosis.

[0031] In this embodiment, a method is also provided for application to the electrical stimulation system, which is capable of generating a combination of electrical stimulation pulses capable of achieving stabilization of glycemic excursions and reducing inflammatory responses.

[0032] Example 1

[0033] [Stabilization of blood sugar fluctuations]

[0034] In order to verify the feasibility of the present invention, first, a human experiment to improve diabetes-related diseases is carried out. This experiment is a multi-center, prospective, double-blind, randomized, placebo-controlled study (clinical trial number: NCT03102424). The electrical stimulation system according to the present invention (see FIG. 6 for the pattern of electrical stimulation pulses) was used on subjects with type 2 diabetes, and the improvement of glycemic control was observed. Type 2 diabetes patients who met all the inclusion criteria and did not meet the exclusion criteria were randomly divided into a group using the electrical stimulation system according to the present invention (hereinafter, TENS group) and a placebo group in a 1:1 ratio. In the placebo group, subjects are given ineffective electrical stimulation pulses. The experimental method is to attach the electrode structure of the electrical stimulation system to both the left and right sides of the subject's abdominal skin, respectively, and use the electrical stimulation system for 1 hour after dinner, 1 hour a day, 5 days a week or more for 20 weeks. Self-monitoring of blood glucose (SMBG) will be performed at seven time points: before three meals, two hours after three meals, and at bedtime during weeks 0, 4, 12, and 20.

[0035] In this example, the test results of the electrical stimulation system are shown in Table 1.

[0036] [Table 1]

[0037] Specifically, in the embodiment of the present invention, the mean amplitude of glycemic excursion (MAGE) was calculated using SMBG data at seven time points as an index of glycemic variability (GV). As shown in FIG. 2 and Table 1, after applying electrical stimulation pulses to the subjects for 20 weeks, it was found that the SMBG data at seven time points in the TENS group decreased from 184 at the baseline state to 173. In the placebo group, it decreased from 180 at the baseline state to 172. After calculation, the mean glycemic excursion MAGE in the TENS group decreased from 85 at the baseline state to 66. In the placebo group, it decreased from 88 at the baseline to 79. It was found that the SMBG data and MAGE at seven time points in the TENS group tended to decrease from week 0 to week 20. The change in MAGE was statistically significant (P=0.009), and it was found that the GV was relatively stable compared to the placebo group.

[0038] Next, the electrical stimulation system according to the present invention was used on subjects with different classification conditions to examine its effects. As shown in Figure 3, when the electrical stimulation system according to the present invention was used on the TENS group and the placebo group, the MAGE in the TENS group was reduced, especially in the female group (P = 0.042), the patient group with glycated hemoglobin (HbA1c) ≥ 8.0% (P = 0.002), and the BMI < 26.9 kg / m 2 A statistically significant difference was observed between the two groups (P=0.047). It was found that the electrical stimulation system according to the present invention reduces MAGE in diabetic patients and is highly effective in stabilizing blood glucose fluctuations.

[0039] Example 2

[0040] [Reduction of inflammatory responses]

[0041] In Example 2, the electrical stimulation system according to the present invention was used on subjects for 20 weeks, and then, whether there was a difference in the inflammatory factors expressed in blood tests was analyzed. As shown in Figures 4 to 5 and Table 1, the results of the experiment showed that after applying electrical stimulation pulses to the subjects, the amount of C-reactive protein (CRP) measured in the TENS group decreased from 0.22 at baseline to 0.16, and increased from 0.24 at baseline to 0.38 in the placebo group. The amount of fibroblast growth factor 21 (FGF-21) protein measured in the TENS group decreased from 0.29 at baseline to 0.24. In the placebo group, it decreased from 0.35 at baseline to 0.32. It was revealed that CRP and FGF-21 from week 0 to week 20 were significantly decreased in the TENS group compared to the placebo group. The data on the reduction in CRP and FGF-21 protein expression indicates that the electrical stimulation system of the present invention can reduce inflammatory cytokines in diabetic patients and suppress the inflammatory response, thereby improving diabetes-related symptoms.

[0042] On the other hand, the change in glycated hemoglobin (HbA1c) is also a noteworthy point. In the embodiment of the present invention, as shown in Table 1, the subjects were given electrical stimulation pulses for 20 weeks, and the HbA1c measured in the TENS group decreased from 8.1 at the baseline to 7.9, and in the placebo group, it decreased from 8.1 at the baseline to 7.8. It was found that there was no significant change in the expression level of HbA1c between the TENS group and the placebo group. Therefore, it was found that the stabilization of blood glucose fluctuations or the reduction of inflammatory responses using the electrical stimulation system of the present invention is not achieved by changing HbA1c.

[0043] As described above, the electrical stimulation system and its application method according to the present invention can achieve stabilization of blood glucose fluctuations and suppress glycemic variability (GV), and can achieve the special effect of suppressing inflammatory responses, which is not available in the prior art.

[0044] The above examples are for explaining the embodiments of the present invention and for explaining the characteristic configuration of the present invention. The present invention is not limited to the above examples. Modifications or equivalent arrangements that can be easily made by those skilled in the art are also within the scope of the present invention. The scope of protection of the rights of the present invention shall be based on the scope of the patent application.

Claims

1. 1. An electrical stimulation system comprising: an electrical stimulation generator that generates a combination of electrical stimulation pulses of 1 to 20,000 Hz, including a first frequency group, a second frequency group, and a third frequency group, each of which is composed of a plurality of monophasic pulse groups having a duty cycle of 50% or more and a square wave waveform; an electrode structure electrically connected to the electrical stimulation generator and having a contact surface for contacting a subject's skin to deliver the combination of electrical stimulation pulses; The combination of electrical stimulation pulses is output in sequence from the first frequency group to the third frequency group, and the frequency range of the first frequency group is 10 to 20,000 Hz, and includes a first monophasic pulse group of 18,122 Hz, a second monophasic pulse group of 10,000 Hz, a third monophasic pulse group of 7,344 Hz, a fourth monophasic pulse group of 5,000 Hz, a fifth monophasic pulse group of 4,200 Hz, a sixth monophasic pulse group of 3,672 Hz, a seventh monophasic pulse group of 3,175 Hz, an eighth monophasic pulse group of 3,000 Hz, and a fifth monophasic pulse group of 4,200 Hz. 9th monophasic pulse group of 127 Hz, 10th monophasic pulse group of 2112 Hz, 11th monophasic pulse group of 2007 Hz, 12th monophasic pulse group of 1865 Hz, 13th monophasic pulse group of 1850 Hz, 14th monophasic pulse group of 1550 Hz, 15th monophasic pulse group of 1234 Hz, 16th monophasic pulse group of 1043 Hz, 17th monophasic pulse group of 1000 Hz, 18th monophasic pulse group of 921 Hz, 19th monophasic pulse group of 880 Hz, 20th monophasic pulse group of 867 Hz, 21st monophasic pulse group of 867 Hz, 22nd monophasic pulse group of 867 Hz, 23rd monophasic pulse group of 1043 Hz, 24th monophasic pulse group of 1000 Hz, 25th monophasic pulse group of 921 Hz, 26th monophasic pulse group of 880 Hz, 27th monophasic pulse group of 867 Hz, 28th monophasic pulse group of 867 Hz, 29th monophasic pulse group of 867 Hz, 30th monophasic pulse group of 867 Hz, 31st monophasic pulse group of 867 Hz, 32nd monophasic pulse group of 867 Hz, 33rd monophasic pulse group of 867 Hz, 34th monophasic pulse group of 867 Hz, 35th monophasic pulse group of 867 Hz, 36th monophasic pulse group of 867 21st monophasic pulse group of 7 Hz, 22nd monophasic pulse group of 778 Hz, 23rd monophasic pulse group of 751 Hz, 24th monophasic pulse group of 730 Hz, 25th monophasic pulse group of 705 Hz, 26th monophasic pulse group of 668 Hz, 27th monophasic pulse group of 652 Hz, 28th monophasic pulse group of 625 Hz, 29th monophasic pulse group of 612 Hz, 30th monophasic pulse group of 595 Hz, 31st monophasic pulse group of 542 Hz, 32nd monophasic pulse group of 522 Hz, 33rd monophasic pulse group of 484 Hz, a monophasic pulse group of 462 Hz, a 34th monophasic pulse group of 462 Hz, a 35th monophasic pulse group of 435 Hz, a 36th monophasic pulse group of 421 Hz, a 37th monophasic pulse group of 380 Hz, a 38th monophasic pulse group of 348 Hz, a 39th monophasic pulse group of 302 Hz, a 40th monophasic pulse group of 160 Hz, a 41st monophasic pulse group of 141 Hz, a 42nd monophasic pulse group of 125 Hz, a 43rd monophasic pulse group of 95 Hz, a 44th monophasic pulse group of 80 Hz, a 45th monophasic pulse group of 66 Hz,The output time of the first frequency group is 2300 to 2350 seconds, the frequency range of the second frequency group is 1 to 30 Hz, the output time of the second frequency group is 2300 to 2350 seconds, the output time of the first frequency group is 2300 to 2350 seconds, the frequency range of the second frequency group is 1 to 30 Hz, the output time of the first frequency group is 2300 to 2350 seconds, the output time of the second frequency group is 2300 to 2350 seconds ... an electrical stimulation system including, in order, a 55th monophasic pulse group at 5 Hz, and a 56th monophasic pulse group at 5 Hz, the output time of the second frequency group being 900 to 1000 seconds, the frequency range of the third frequency group being 5 to 30 Hz, and including, in order, a 57th monophasic pulse group at 6 Hz, a 58th monophasic pulse group at 7 Hz, a 59th monophasic pulse group at 8 Hz, a 60th monophasic pulse group at 17 Hz, and a 61st monophasic pulse group at 26 Hz, the output time of the third frequency group being 320 to 400 seconds.

2. 2. The electrical stimulation system according to claim 1, wherein the output time of the combination of electrical stimulation pulses is 3520 to 3750 seconds.

3. 2. The electrical stimulation system of claim 1, wherein the combination of electrical stimulation pulses further comprises a potential difference of less than 10 Vpp.

4. 2. The electrical stimulation system of claim 1, wherein the electrode structure contacts the subject's abdominal skin.

5. 2. The electrical stimulation system of claim 1, wherein the electrical stimulation system improves the symptoms of diabetes by achieving stabilization of blood sugar fluctuations or reducing inflammatory responses.

6. The electrical stimulation system according to claim 5, wherein the electrical stimulation system achieves stabilization of blood glucose fluctuation by suppressing blood glucose variability (GV).

7. The electrical stimulation system according to claim 5, wherein the electrical stimulation system reduces the inflammatory response by reducing the expression levels of C-reactive protein (CRP) and fibroblast growth factor 21 (FGF-21).

Images